Recombinant Human FGF-17
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Description | FGF-17 is a heparin binding growth factor that is a member of the FGF family. Proteins of this family play a central role during prenatal development and postnatal growth and regeneration of a variety of tissues, by promoting cellular proliferation and differentiation. FGF-17 signals through the FGFR 1c, 2c, 3c, and 4. FGF-17 signals induction and patterning of embryonic brain. Recombinant human FGF-17 is a 22.7 kDa protein consisting of 195 amino acid residues. |
---|---|
BiologicalActivity | Assay #1: The ED50 as determined by the dose-dependent stimulation of thymidine uptake by BaF3 cells expressing FGF-receptors is ≤ 0.5 ng/ml, corresponding to a specific activity of ≥ 2 x 106 units/mg. Assay #2: The ED50 was determined by a cell proliferation assay using balb/c 3T3 cells is ≤ 10.0 ng/ml, corresponding to a specific activity of ≥ 1 x 105 units/mg. |
Authenticity | Verified by N-terminal and Mass Spectrometry analyses (when applicable). |
Endotoxin | Endotoxin level is <0.1 ng/ µg of protein (<1EU/ µg). |
Protein Content | Verified by UV Spectroscopy and/or SDS-PAGE gel. |
Storage | -20°C |
Precautions | Recombinant Human FGF-17 is for research use only and not for use in diagnostic or therapeutic procedures. |

Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.

If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.